Aura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 11,822 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 11,822 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the completion of the transaction, the insider now owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Aura Biosciences Price Performance

AURA stock traded down $0.33 during trading on Monday, hitting $9.14. 485,472 shares of the stock traded hands, compared to its average volume of 177,115. Aura Biosciences, Inc. has a 1 year low of $6.63 and a 1 year high of $12.38. The firm’s 50 day moving average is $9.82 and its two-hundred day moving average is $8.54. The stock has a market cap of $456.54 million, a price-to-earnings ratio of -5.28 and a beta of 0.33.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.02. As a group, analysts anticipate that Aura Biosciences, Inc. will post -1.69 EPS for the current fiscal year.

Institutional Trading of Aura Biosciences

Several institutional investors have recently bought and sold shares of AURA. Long Focus Capital Management LLC grew its position in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. grew its stake in shares of Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares during the period. Wellington Management Group LLP bought a new stake in shares of Aura Biosciences in the third quarter worth approximately $1,037,000. Bank of New York Mellon Corp grew its stake in shares of Aura Biosciences by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after acquiring an additional 48,549 shares during the period. Finally, Barclays PLC grew its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after acquiring an additional 43,897 shares during the period. 96.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. BTIG Research upped their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Thursday. Scotiabank upped their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. Finally, JMP Securities upped their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.